{"id":279273,"date":"2026-09-30T09:46:58","date_gmt":"2026-09-30T04:16:58","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=279273"},"modified":"2026-09-30T09:46:58","modified_gmt":"2026-09-30T04:16:58","slug":"why-astrazeneca-pharma-india-ltd-share-near-52-week-consecutive-low-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-near-52-week-consecutive-low-2026\/","title":{"rendered":"Astrazeneca Pharma India Ltd. (ASTRAZEN) 52 Week Low Streak: Second Straight Session Near Yearly Low"},"content":{"rendered":"<div class=\"univest-blue-summary\" style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:12px 16px;margin:0 0 18px 0;font-style:italic;\"><em><a href=\"https:\/\/univest.in\/stocks\/astrazen\/astrazeneca-pharma-india-ltd-share-price-today\">Astrazeneca Pharma India Ltd. (ASTRAZEN)<\/a> share price is trading within 2% of its 52-week low today and stood at Rs 6,275.45, up 0.34% from the previous close. Market cap was Rs 15,635.88 crore.<\/em><\/div>\n<p style=\"margin-top:0!important;\"><strong>Astrazeneca Pharma India Ltd. 52 Week Low Streak<\/strong> has now extended to its second straight session, with the stock still trading within 2% of its 52-week low. Across the streak, the share has slipped 0.19%, and the latest trough remains the key reference point for readers tracking the <strong>Astrazeneca Pharma India Ltd. 52 Week Low Streak<\/strong>. The supplied data confirms the repeated-low pattern, but it does not establish a company-specific cause for the continued weakness.<\/p>\n<p>The stock closed at Rs 6275.45 versus the previous close of Rs 6254.35, after opening at Rs 6225.65 and touching an intraday high of Rs 6280 and a low of Rs 6225.65. The market capitalisation stands at Rs 15,635.88 crore. For readers, the point is not just the one-session change; it is the persistence of the <strong>Astrazeneca Pharma India Ltd. 52 Week Low Streak<\/strong> across consecutive trading days, which keeps the yearly low in focus as a live market signal.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-near-52-week-consecutive-low-2026\/#Astrazeneca_Pharma_India_Ltd_52_Week_Low_Streak_Consecutive_Low_Analysis\" title=\"Astrazeneca Pharma India Ltd. 52 Week Low Streak: Consecutive Low Analysis\">Astrazeneca Pharma India Ltd. 52 Week Low Streak: Consecutive Low Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-near-52-week-consecutive-low-2026\/#What_The_Repeated_52-Week_Lows_Show\" title=\"What The Repeated 52-Week Lows Show\">What The Repeated 52-Week Lows Show<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-near-52-week-consecutive-low-2026\/#Astrazeneca_Pharma_India_Ltd_ASTRAZEN_Fundamental_Analysis\" title=\"Astrazeneca Pharma India Ltd. (ASTRAZEN) Fundamental Analysis\">Astrazeneca Pharma India Ltd. (ASTRAZEN) Fundamental Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-near-52-week-consecutive-low-2026\/#Sector_and_Industry_Context\" title=\"Sector and Industry Context\">Sector and Industry Context<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-near-52-week-consecutive-low-2026\/#Peer_Comparison\" title=\"Peer Comparison\">Peer Comparison<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-near-52-week-consecutive-low-2026\/#Why_Investors_Are_Watching\" title=\"Why Investors Are Watching\">Why Investors Are Watching<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-near-52-week-consecutive-low-2026\/#About_The_Company\" title=\"About The Company\">About The Company<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-near-52-week-consecutive-low-2026\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-near-52-week-consecutive-low-2026\/#Why_is_Astrazeneca_Pharma_India_Ltd_still_near_its_52-week_low\" title=\"Why is Astrazeneca Pharma India Ltd. still near its 52-week low?\">Why is Astrazeneca Pharma India Ltd. still near its 52-week low?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-near-52-week-consecutive-low-2026\/#What_does_the_Astrazeneca_Pharma_India_Ltd_52_Week_Low_Streak_mean\" title=\"What does the Astrazeneca Pharma India Ltd. 52 Week Low Streak mean?\">What does the Astrazeneca Pharma India Ltd. 52 Week Low Streak mean?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-near-52-week-consecutive-low-2026\/#Is_Astrazeneca_Pharma_India_Ltd_under_pressure_compared_with_peers\" title=\"Is Astrazeneca Pharma India Ltd. under pressure compared with peers?\">Is Astrazeneca Pharma India Ltd. under pressure compared with peers?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-near-52-week-consecutive-low-2026\/#How_strong_are_the_profitability_ratios\" title=\"How strong are the profitability ratios?\">How strong are the profitability ratios?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-near-52-week-consecutive-low-2026\/#What_is_the_current_market_capitalisation_of_Astrazeneca_Pharma_India_Ltd\" title=\"What is the current market capitalisation of Astrazeneca Pharma India Ltd.?\">What is the current market capitalisation of Astrazeneca Pharma India Ltd.?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-near-52-week-consecutive-low-2026\/#Does_the_data_confirm_a_reversal_from_the_low\" title=\"Does the data confirm a reversal from the low?\">Does the data confirm a reversal from the low?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-near-52-week-consecutive-low-2026\/#How_should_readers_interpret_the_repeated_low_pattern\" title=\"How should readers interpret the repeated low pattern?\">How should readers interpret the repeated low pattern?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-near-52-week-consecutive-low-2026\/#Where_does_Astrazeneca_Pharma_India_Ltd_stand_in_the_healthcare_sector\" title=\"Where does Astrazeneca Pharma India Ltd. stand in the healthcare sector?\">Where does Astrazeneca Pharma India Ltd. stand in the healthcare sector?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-near-52-week-consecutive-low-2026\/#Track_Astrazeneca_Pharma_India_Ltd_ASTRAZEN_Share_Price_on_Univest\" title=\"Track Astrazeneca Pharma India Ltd. (ASTRAZEN) Share Price on Univest\">Track Astrazeneca Pharma India Ltd. (ASTRAZEN) Share Price on Univest<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Astrazeneca_Pharma_India_Ltd_52_Week_Low_Streak_Consecutive_Low_Analysis\"><\/span><strong>Astrazeneca Pharma India Ltd. 52 Week Low Streak: Consecutive Low Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:16px 0 22px 0;\">\n<tr>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Metric<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Value<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Current Price<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 6,275.45<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Previous Close<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 6,254.35<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Today&#39;s Move<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">+Rs 21.1 (+0.34%)<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Open<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 6,225.65<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>High<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 6,280<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Low<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 6,225.65<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Market Capitalisation<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 15,635.88 crore<\/td>\n<\/tr>\n<\/table>\n<p>Astrazeneca Pharma India Ltd. (ASTRAZEN) traded at Rs 6,275.45 versus the previous close of Rs 6,254.35, a rise of 0.34%. The stock opened at Rs 6,225.65, reached a high of Rs 6,280, touched a low of Rs 6,225.65.<\/p>\n<p><strong>Astrazeneca Pharma India Ltd. 52 Week Low Streak<\/strong> began with a narrow session around the lower end of the day\u2019s range, and today\u2019s move kept that pattern intact. The share price finished at Rs 6275.45, up Rs 21.10 or 0.34% from the previous close of Rs 6254.35. The day\u2019s open at Rs 6225.65 was below the close, while the high of Rs 6280 capped the session only slightly above the closing level. The low for the day was also Rs 6225.65, which means the stock spent the entire session near the bottom of its range.<\/p>\n<p>That detail matters because the <strong>Astrazeneca Pharma India Ltd. 52 Week Low Streak<\/strong> is not being driven by a single sharp shock alone; it is persisting across sessions. The current level remains very close to the one-year trough, and the move across the streak remains modest at -0.19%. In the context of <strong>Astrazeneca Pharma India Ltd. Share Price<\/strong> reporting, this is a decline story rather than a recovery story, with the yearly low acting as the main reference zone. The market capitalisation of Rs 15,635.88 crore places the stock firmly among the more closely watched names in the healthcare pack.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_The_Repeated_52-Week_Lows_Show\"><\/span><strong>What The Repeated 52-Week Lows Show<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Astrazeneca Pharma India Ltd. 52 Week Low Streak<\/strong> is important because it shows persistence, not just an isolated weak day. The stock has traded within 2% of its 52-week low for a second straight session, which keeps the one-year trough in the frame for traders, analysts and long-term readers following <strong>Astrazeneca Pharma India Ltd. Stock News<\/strong>. The supplied data confirms the pattern of repeated lows, but it does not identify a company-specific catalyst behind the move.<\/p>\n<p>In practical terms, back-to-back proximity to a yearly low often tells the market that the stock is not yet finding a stable base. That does not mean a fresh breakdown has been confirmed today, and it does not mean a reversal is due either. It simply means the <strong>Astrazeneca Pharma India Ltd. 52 Week Low Streak<\/strong> remains active and that the stock continues to sit in the zone that investors commonly associate with <strong>52 Week Low Stocks<\/strong> and <strong>Stocks At One Year Low Today<\/strong>. The fact that the current low remains the key reference point is the main story, not the daily gain or loss.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Astrazeneca_Pharma_India_Ltd_ASTRAZEN_Fundamental_Analysis\"><\/span><strong>Astrazeneca Pharma India Ltd. (ASTRAZEN) Fundamental Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:16px 0 22px 0;\">\n<tr>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Metric<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Value<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Market Capitalisation<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 15,635.88 crore<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>P\/E Ratio<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">92.18x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>P\/B Ratio<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">17.29x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>ROE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">23.02%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>ROCE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">31.24%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>EPS<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 67.85<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Book Value Per Share<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 361.68<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Dividend Yield<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">0.58%<\/td>\n<\/tr>\n<\/table>\n<p>Astrazeneca Pharma India Ltd. (ASTRAZEN) fundamental metrics show P\/E 92.18x, P\/B 17.29x, ROE 23.02%, ROCE 31.24%. These figures provide context only and are not a buy or sell signal.<\/p>\n<p>Astrazeneca Pharma India Ltd. has a market capitalisation of Rs 15635.88 crore, which gives readers a sense of company size before judging valuation. On valuation, P\/E at 92.18x, P\/B at 17.29x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 23.02% and ROCE of 31.24%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 67.85, book value per share of Rs 361.68, dividend yield of 0.58%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P\/E of 28.2x, median ROE of 11.7%, median ROCE of 13.46%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Sector_and_Industry_Context\"><\/span><strong>Sector and Industry Context<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:16px 0 22px 0;\">\n<tr>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Metric<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Value<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Sector<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Healthcare<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Industry<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Pharmaceuticals &amp; Drugs<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Scope<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">same industry<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company P\/E Ratio<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">92.18x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median P\/E<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">28.2x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Average P\/E<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">41.75x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark P\/E Range<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">0x to 699.02x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company P\/B Ratio<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">17.29x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median P\/B<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">2.87x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company ROE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">23.02%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median ROE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">11.7%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company ROCE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">31.24%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median ROCE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">13.46%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company Market Capitalisation<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 15,635.88 crore<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median Market Cap<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 773.14 crore<\/td>\n<\/tr>\n<\/table>\n<p>Astrazeneca Pharma India Ltd. (ASTRAZEN) is classified under sector: Healthcare and industry: Pharmaceuticals &amp; Drugs.<\/p>\n<p>Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P\/E ratio of 92.18x, which is above the benchmark median of 28.2x, a difference of +226.88%. P\/E is a valuation multiple and is not, by itself, a buy or sell signal.<\/p>\n<p>Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROE of 23.02%, which is above the benchmark median of 11.7%, a difference of +96.75%. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROCE of 31.24%, which is above the benchmark median of 13.46%, a difference of +132.1%.<\/p>\n<p>Track stocks falling to yearly lows through the <a href=\"https:\/\/univest.in\/screeners\/52-week-low\">Univest 52-week-low screener<\/a>. The peer table below provides the company-level comparison.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Peer_Comparison\"><\/span><strong>Peer Comparison<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:16px 0 22px 0;\">\n<tr>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">Company<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">Symbol<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">Market Cap (Cr)<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">P\/E<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">P\/B<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">ROE (%)<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">ROCE (%)<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/marksans\/marksans-pharma-ltd-share-price-today\" style=\"color:#0645AD;text-decoration:underline;\"><strong>Marksans Pharma Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">MARKSANS<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">15,026.91<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">30.06<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">4.89<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">15.31<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">21.1<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/natcopharm\/natco-pharma-ltd-share-price-today\" style=\"color:#0645AD;text-decoration:underline;\"><strong>Natco Pharma Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">NATCOPHARM<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">14,832.09<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">13.21<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">1.62<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">16.3<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">17.16<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/alivus\/glenmark-life-sciences-ltd-share-price-today\" style=\"color:#0645AD;text-decoration:underline;\"><strong>Glenmark Life Sciences Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">ALIVUS<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">16,695.69<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">27.69<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">4.79<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">18.41<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">24.61<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/concordbio\/concord-biotech-ltd-share-price-today\" style=\"color:#0645AD;text-decoration:underline;\"><strong>Concord Biotech Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">CONCORDBIO<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">14,585.07<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">53.56<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">7.11<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">13.54<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">18.04<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/aplltd\/alembic-pharmaceuticals-ltd-share-price-today\" style=\"color:#0645AD;text-decoration:underline;\"><strong>Alembic Pharmaceuticals Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">APLLTD<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">16,790.42<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">24.38<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">2.89<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">12.35<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">11.74<\/td>\n<\/tr>\n<\/table>\n<p>Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P\/E ratio of 92.18x compared with the displayed peer median of 27.69x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 23.02% compares with a peer median of 15.31% across the companies shown in the table. ROCE stood at 31.24% versus the displayed peer median of 18.04%, providing a capital-efficiency comparison. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a market capitalisation of Rs 15,635.88 crore. Among the 5 peers shown, 2 have a larger market capitalisation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Investors_Are_Watching\"><\/span><strong>Why Investors Are Watching<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Astrazeneca Pharma India Ltd. 52 Week Low Streak<\/strong> has continued for a second straight session, keeping the yearly low in focus.<\/li>\n<li>The stock\u2019s <strong>Astrazeneca Pharma India Ltd. Share Price<\/strong> remains close to its 52-week trough, so readers are tracking whether the low zone stabilises.<\/li>\n<li>The supplied data confirms the repeated-low pattern, but it does not establish a company-specific cause.<\/li>\n<li>Valuation remains rich versus the industry median, even though return ratios are comparatively strong.<\/li>\n<li>Healthcare sector and pharmaceutical peer comparison help frame whether the current <strong>Astrazeneca Pharma India Ltd. Stock Performance<\/strong> is isolated or part of a wider re-rating.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"About_The_Company\"><\/span><strong>About The Company<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Astrazeneca Pharma India Ltd. operates in the Healthcare sector and the Pharmaceuticals &amp; Drugs industry. The company\u2019s current market capitalisation is Rs 15,635.88 crore, and the latest market read keeps the <strong>Astrazeneca Pharma India Ltd. 52 Week Low Streak<\/strong> under close watch. As a listed pharmaceutical company, it is followed for its financial quality, earnings profile and comparative valuation within the domestic healthcare space.<\/p>\n<p>For investors and market readers, the relevant context is not only the daily price movement but how the stock behaves relative to its one-year low, its sector peers and its stated fundamentals. That is why <strong>Astrazeneca Pharma India Ltd. Share Price<\/strong>, valuation ratios and profitability metrics all matter together when assessing the current phase of weakness.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Registration Number INH000013776), a subsidiary of Univest Communication Technologies Private Limited.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Why_is_Astrazeneca_Pharma_India_Ltd_still_near_its_52-week_low\"><\/span><strong>Why is Astrazeneca Pharma India Ltd. still near its 52-week low?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The supplied data shows that Astrazeneca Pharma India Ltd. has traded within 2% of its 52-week low for a second straight session. It confirms the pattern, but it does not identify a company-specific reason for the continued weakness.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_does_the_Astrazeneca_Pharma_India_Ltd_52_Week_Low_Streak_mean\"><\/span><strong>What does the Astrazeneca Pharma India Ltd. 52 Week Low Streak mean?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> It means the stock has remained close to its yearly low for consecutive sessions. For this Astrazeneca Pharma India Ltd. 52 Week Low Streak, the move across the streak is -0.19%, which keeps the breakdown in focus.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Astrazeneca_Pharma_India_Ltd_under_pressure_compared_with_peers\"><\/span><strong>Is Astrazeneca Pharma India Ltd. under pressure compared with peers?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The stock trades at a much higher P\/E and P\/B than the industry median and several named peers. That makes the Astrazeneca Pharma India Ltd. Share Price look expensive relative to many comparables in the same industry.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_strong_are_the_profitability_ratios\"><\/span><strong>How strong are the profitability ratios?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> ROE is 23.02% and ROCE is 31.24%, both above the supplied industry medians. The Astrazeneca Pharma India Ltd. Stock Analysis therefore shows stronger return ratios even though the price remains near the yearly low.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_current_market_capitalisation_of_Astrazeneca_Pharma_India_Ltd\"><\/span><strong>What is the current market capitalisation of Astrazeneca Pharma India Ltd.?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The company\u2019s market capitalisation is Rs 15,635.88 crore. That size matters when reading the Astrazeneca Pharma India Ltd. Stock News because it places the name among closely tracked pharmaceutical companies in the healthcare space.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Does_the_data_confirm_a_reversal_from_the_low\"><\/span><strong>Does the data confirm a reversal from the low?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. The stock closed slightly higher on the day, but the Astrazeneca Pharma India Ltd. 52 Week Low Streak is still intact. The supplied numbers do not support a conclusion that the broader weakness has ended.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_should_readers_interpret_the_repeated_low_pattern\"><\/span><strong>How should readers interpret the repeated low pattern?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> They should treat it as a price-pattern signal, not a cause-based explanation. The repeated proximity to the yearly low suggests the stock remains in a weak zone, while the underlying reason remains unconfirmed in the supplied data.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Where_does_Astrazeneca_Pharma_India_Ltd_stand_in_the_healthcare_sector\"><\/span><strong>Where does Astrazeneca Pharma India Ltd. stand in the healthcare sector?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Within the Healthcare sector and Pharmaceuticals &amp; Drugs industry, the company stands out for its premium valuation and solid profitability ratios. The Astrazeneca Pharma India Ltd. 52 Week Low Streak shows the price is not matching those fundamentals in the.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Track_Astrazeneca_Pharma_India_Ltd_ASTRAZEN_Share_Price_on_Univest\"><\/span><strong>Track Astrazeneca Pharma India Ltd. (ASTRAZEN) Share Price on Univest<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Use <a href=\"https:\/\/univest.in\/stocks\/astrazen\/astrazeneca-pharma-india-ltd-share-price-today\">Astrazeneca Pharma India Ltd. (ASTRAZEN) live share-price page<\/a>, <a href=\"https:\/\/univest.in\/screeners\/52-week-low\">Univest 52-week-low screener<\/a>, <a href=\"https:\/\/univest.in\/blogs\">Univest market blogs<\/a> to review live stock data, yearly-low lists and related market analysis.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Astrazeneca Pharma India Ltd. Share Price trades near its 52-week low at Rs 6,275.45, marking a 0.34% decline today. Market cap stands at Rs 15,635.88 crore.<\/p>\n","protected":false},"author":38,"featured_media":279271,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-279273","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["279271"],"rank_math_title":["Astrazeneca Pharma India 52 Week Low Streak: Second Session"],"rank_math_description":["Astrazeneca Pharma India Ltd. has traded near its 52-week low for a second straight session. See price action, valuation, peers and key risks."],"rank_math_focus_keyword":["Astrazeneca Pharma India Ltd. 52 Week Low Streak"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/09\/astrazeneca-pharma-india-ltd-astrazen-52-week-low-streak-second-straight-session.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/279273","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=279273"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/279273\/revisions"}],"predecessor-version":[{"id":279275,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/279273\/revisions\/279275"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/279271"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=279273"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=279273"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=279273"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}